Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic
inflammation extending to a variable extent from the rectum. Care of the patient with UC …

Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Cytokines are involved in intestinal homeostasis and pathological processes associated
with inflammatory bowel disease (IBD). The biological effects of cytokines, including several …

Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are
characterized by uncontrolled activation of intestinal immune cells in a genetically …

Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disorder of the colon that
causes continuous mucosal inflammation extending from the rectum to the more proximal …

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal
tract. Cytokine-targeted therapies have transformed the treatment of IBD, providing control of …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Background Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have
potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further …